Pulmonary and Critical Care Clinical Trials
The following searchable list includes all the Division of Pulmonary and Critical Care - Department of Medicine clinical trials currently looking for participants. Please feel free to contact us with inquiries about any of our ongoing research.
Trials |
---|
A Registry of Interstitial Lung Disease PatientsThe purpose of this registry is to collect clinical information about people with interstitial lung disease (ILD) to help us better understand the causes of ILD and determine if particular types of treatment work better for some causes of ILD than others. The Registry will also be used to determine … The purpose of this registry is to collect clinical information about people with interstitial lung disease (ILD) to help us better understand the causes of ILD and determine if particular types of treatment work better for some causes of ILD than others. The Registry will also be used to determine who might be eligible for and interested in participating in future studies related to ILD. Participants agree to allow the collection of information from the medical record for research purposes and agree to allow us to contact them about future studies. Participants may also complete questionnaires during their standard of care visits, participate in an optional frailty study by taking a brief physical ability test at the time of standard of care visits, give optional blood for research, and optionally allow us to contact them about their health on an annual basis. |
INtervention Study In OverweiGHT Patients with COPD (INSIGHT COPD)We are conducting the INSIGHT COPD study because symptoms of chronic obstructive pulmonary disease (COPD) and high body mass index (BMI) overlap. There are many medications for patients with COPD, but there is little mention of weight loss as a possible treatment in current research. We are trying to find … We are conducting the INSIGHT COPD study because symptoms of chronic obstructive pulmonary disease (COPD) and high body mass index (BMI) overlap. There are many medications for patients with COPD, but there is little mention of weight loss as a possible treatment in current research. We are trying to find out if a lifestyle program that promotes modest weight loss and increased physical activity will improve COPD symptoms for those with a high BMI. We hope that the program will lead to weight loss and better exercise tolerance. We are also looking at the effects on shortness of breath, quality-of-life, and cardiovascular disease risk factors. 1 year, 2 visits. 40 years of age or older with COPD, wants to participate in a healthy lifestyle intervention, body mass index of 25 -44.9
NCT02634268 STU00204332 |
Pathogenic Wnt-beta catenin target genes in macrophages and fibrosisThe purpose of this study is to better understand the development of scleroderma-related lung fibrosis (ILD). We would like to investigate the role of macrophages and other important cells in the development of ILD. Macrophages are types of white blood cells important in the immune system. In healthy people, … The purpose of this study is to better understand the development of scleroderma-related lung fibrosis (ILD). We would like to investigate the role of macrophages and other important cells in the development of ILD. Macrophages are types of white blood cells important in the immune system. In healthy people, macrophages produce proteins that activate the immune system to assist in tissue repair. However, there is evidence that in people with scleroderma, the macrophages behave abnormally and contribute to scarring in the lungs. Patients who participate in this study will:
STU00207083 |
A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic and Additional Strategies in Hospitalized Adults with COVID-19Patients with COVID-19 disease are at risk of blood clots, which may affect many parts of the body. It is recommended that patients hospitalized with COVID-19 disease be placed on a blood thinner called heparin to prevent clots. The purpose of this study is to determine if adding … Patients with COVID-19 disease are at risk of blood clots, which may affect many parts of the body. It is recommended that patients hospitalized with COVID-19 disease be placed on a blood thinner called heparin to prevent clots. The purpose of this study is to determine if adding a platelet inhibitor, a different type of blood thinner, will be even better at reducing the risk of blood clots. All of these blood thinner medications are already approved by the United States Food and Drug Administration (FDA) for preventing clots in different situations. We do not currently know the best combination of these drugs in people hospitalized with COVID-19. Participants in this study will receive an assigned study treatment that will last up to 14 days or until discharge from the hospital, whichever comes first. The study team will also contact participants about 90 days after hospital discharge and about 1 year after hospital discharge to check on the participant's health. Currently, participants will be randomly assigned to either blood thinner alone or blood thinner with platelet inhibitor. Participants may also optionally give blood samples at four different times during their hospital stay. The blood will be stored for future genetic research.
NCT04505774 STU00213958 |
Macitentan in inoperAble or persistent/reCurrent chronIc ThromboEmbolic Pulmonary Hypertension (MACiTEPH) - A prospective, randomized, double-blind, multicenter, placebo-controlled, parallel group, adaptive Phase 3 study with open-label extension to evaluate efficacy and safety of macitentan 75 mg in inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertensionThe purpose of this trial is to see if macitentan 75 mg versus placebo is useful and safe for treating patients with chronic thromboembolic pulmonary hypertension (CTEPH). Macitentan 10 mg once-daily is approved in many countries around the world for the treatment of pulmonary arterial hypertension (PAH). Macitentan at … The purpose of this trial is to see if macitentan 75 mg versus placebo is useful and safe for treating patients with chronic thromboembolic pulmonary hypertension (CTEPH). Macitentan 10 mg once-daily is approved in many countries around the world for the treatment of pulmonary arterial hypertension (PAH). Macitentan at a dose of 75 mg is not approved for use by any Regulatory Authority in any country. This means that macitentan is an investigational drug, since it is not approved for use in patients with CTEPH, and can only be used in a research study such as this one. Participants will be in this study for up to 3.5 years. Participants who choose to join the open label part of the study will be in the study between 2.5 and 6 years. Participants will:
Participants will be paid a stipend after completion of each study visit.
NCT04271475 STU00212942 |
Immune response to SARS-CoV-2 vaccination in sarcoidosisThe purpose of this study is to investigate the antibody and immune responses to the COVID-19 vaccine in patients with sarcoidosis, both treated and not treated with immunosuppressive medications, compared to healthy controls. This study will address a critical gap in our understanding of vaccine responses in people with … The purpose of this study is to investigate the antibody and immune responses to the COVID-19 vaccine in patients with sarcoidosis, both treated and not treated with immunosuppressive medications, compared to healthy controls. This study will address a critical gap in our understanding of vaccine responses in people with sarcoidosis. Participants will:
Sarcoidosis Patients
Controls
STU00215567 |